These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9728529)

  • 1. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients.
    Roberts TC; Brennan DC; Buller RS; Gaudreault-Keener M; Schnitzler MA; Sternhell KE; Garlock KA; Singer GG; Storch GA
    J Infect Dis; 1998 Sep; 178(3):626-35. PubMed ID: 9728529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Kamil E
    Am J Transplant; 2002 Aug; 2(7):671-3. PubMed ID: 12201370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients.
    Piiparinen H; Helanterä I; Lappalainen M; Suni J; Koskinen P; Grönhagen-Riska C; Lautenschlager I
    J Med Virol; 2005 Jul; 76(3):367-72. PubMed ID: 15902704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes.
    Kühn JE; Wendland T; Schäfer P; Möhring K; Wieland U; Elgas M; Eggers HJ
    J Med Virol; 1994 Dec; 44(4):398-405. PubMed ID: 7897371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
    Boivin G; Handfield J; Toma E; Lalonde R; Bergeron MG
    J Infect Dis; 1999 May; 179(5):1101-7. PubMed ID: 10191210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction and diagnosis of cytomegalovirus disease in renal transplant recipients using qualitative and quantitative polymerase chain reaction.
    Tong CY; Cuevas LE; Williams H; Bakran A
    Transplantation; 2000 Mar; 69(5):985-91. PubMed ID: 10755562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J; Rotjanapan P; Watcharananan SP
    Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ganciclovir resistance in cytomegalovirus infection of renal transplant recipients in Tehran.
    Javad Hosseini SM; Nemati E; Behzadian F; Einollahi B; Rahimi Petrudy A; Sohraby M; Taghipour M; Motalebi M
    Transplant Proc; 2015 May; 47(4):1140-2. PubMed ID: 26036539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation.
    Sia IG; Wilson JA; Groettum CM; Espy MJ; Smith TF; Paya CV
    J Infect Dis; 2000 Feb; 181(2):717-20. PubMed ID: 10669361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.